Company cases
Biosergen: A big step
Biosergen has received approval for the next step in its phase 1 study of its drug against deadly fungal infections,
17. January 2023
We have decades of experience in analyzing small and mid-cap stocks as well as disseminating this information to retail investors. With investment cases, we provide free information on investment opportunities within the segment of Nordic small and mid-caps companies for primarily a Nordic investing audience.
If you want to contact us directly, find contact details for the individual employee under Line Up.
Biosergen has received approval for the next step in its phase 1 study of its drug against deadly fungal infections,
The total return on the Nordic growth exchanges was -44% in 2022. Although none of the sectors managed to deliver
Nordic growth exchanges lost ground in 2022 compared to large cap, but again emerging markets hosted spectacular returns for individual
2022 was a disappointing year for Nordic growth exchanges. However, they have done very well so far in 2023, and
The Nordic growth exchanges had a mixed market performance, with the small exchanges falling and the large exchanges rising. The
Biosergen AB stands in front of near-term price triggers and has a solid capital base to continue the development of
The sentiment on the Nordic growth exchanges was mostly positive during the week. The healthcare sector in particular delivered high
Lifecare is trading at NOK 2.5, the price of the recently completed private placement, and there is therefore no need
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.